Research Comparison
CJC-1295 (without DAC) vs Ipamorelin
A side-by-side research comparison of CJC-1295 (without DAC) and Ipamorelin drawn from Cobalt Peptides' peptide database records.
CJC-1295 (without DAC)
CJC-1295 (without DAC), also known as Modified GRF 1-29 (Mod GRF 1-29), is a short-acting synthetic analog of growth hormone releasing hormone (GHRH). It is designed to stimulate endogenous growth hormone (GH) release in a pulsatile, physiologically consistent manner. Unlike the DAC-modified version, this variant has a very short half-life, allowing precise control over GH pulses and reducing the risk of receptor desensitization. It is primarily used in research focused on recovery, anti-aging, body composition, and endocrine function optimization.
Ipamorelin
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates endogenous growth hormone (GH) secretion via activation of ghrelin (GHS-R1a) receptors in the pituitary. It is characterized by a highly selective profile, producing GH release without significant stimulation of cortisol or prolactin. This selectivity distinguishes it from earlier GHRPs, making it a preferred compound in research focused on body composition, recovery, sleep, and anti-aging. Its ability to preserve physiological GH pulsatility while minimizing off-target endocrine effects has positioned it as a core peptide in GH optimization protocols.